

### **Note**

Pursuant to Proviso 6(a) of Section 136 of the Companies Act, 2013, accounts of Lupin Pharmaceuticals, Inc., USA, Gavis Pharmaceuticals, LLC, USA, Novel Laboratories Inc., USA, Lupin Research Inc., USA, Lupin IP Ventures Inc., USA and Sybiomix Therapeutics LLC, USA, wholly-owned Subsidiaries of Lupin Inc., USA have been consolidated with Lupin Inc., USA, wholly-owned Subsidiary of Lupin Limited ('Company'). Accordingly, Audited Consolidated Financial Statements of Lupin Inc., USA for the year ended March 31, 2019, have been placed on the website of the Company.